Spinal Modulation Revenue and Competitors

FOCUS YOUR THERAPY. BROADEN YOUR POSSIBILITIES. Spinal Modulation is dedicated to improving the lives of patients with chronic pain by providing the next generation of neuromodulation systems through targeted spinal cord stimulation (SCS) of the dorsal root ganglion (DRG). Spinal Modulation is a global medical device company based in Menlo Park, California, Belgium, & Australia. The company is funded by St, Jude Medical, Johnson & Johnson Dev Corp, Medtronic, Kleiner Perkins Caufield & Byers, De Novo Ventures, MedVenture Assoc, InCube Ventures, ePlanet Ventures, Raffles Venture Partners, The Angels Forum & The Halo Fund. St. Jude Medical has the exclusive option to acquire the company following the achievement of certain milestones and is the exclusive distributor of the Axium® Neurostimulator System in international markets where it is approved for sale. AXIUM® NEUROSTIMULATOR SYSTEM The Axium Neurostimulator System is a form of SCS that targets a neural structure within the spine called the dorsal root ganglion. The DRG contains the primary sensory neurons that transmit pain signals from the peripheral nerves to the brain. The system uses an implantable medical device to deliver mild electrical pulses to the DRG. These pulses mask or interrupt pain signals as they travel to the brain. AROUND THE GLOBE The Axium SCS System has both CE Mark & TGA approval and is helping patients at pain centers around the world, including Europe & Australia. Over 800 patients have been treated worldwide with the 1st implant performed in 2011. IN THE UNITED STATES The ACCURATE Study is a prospective, randomized, multi-center, controlled study to evaluate the safety & efficacy of the Axium Neurostimulator System for the treatment of chronic pain affecting the lower limbs. It is the largest U.S. pivotal trial to evaluate spinal cord stimulation therapy in patients with lower limb pain due to nerve injuries (peripheral causalgia) or complex regional pain syndrome (CRPS).